† Study has passed its completion date and status has not been verified in more than two years.
Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL
|4||Active, not recruiting||
BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib